eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
4/2022
vol. 8
 
Share:
Send email
Share:
abstract:
Original paper

Autoantibodies: are they a clue for liver diseases?

Salma Abdel Megeed Nagi
1
,
Bassam Abdel Hakam Ayoub
1
,
Mohammed Abdel-Hafez Ali
1
,
Sally Waheed Elkhadry
2
,
Heba Mohamed Abdallah
3
,
Marwa Sabry Rizk
1

  1. Department of Pediatric Hepatology, Gastroenterology and Nutrition, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt
  2. Department of Epidemiology and Preventive Medicine, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt
  3. Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin El-Kom, Menoufia, Egypt
Clin Exp HEPATOL 2022; 8, 4: 309-314
DOI: https://doi.org/10.5114/ceh.2022.122275
Online publish date: 2022/12/28
View full text Get citation
 
PlumX metrics:
Introduction
Autoantibody testing has contributed to both biological and clinical insights in managing patients with liver disease. These autoantibodies often have clinical value for the diagnosis, disease activity and/or prognosis.

Aim of the study
We aimed to investigate the potential application of auto-antibodies in different etiologies of non-autoimmune liver diseases.

Material and methods
This study was conducted on 53 infants and children with chronic liver diseases. The patients were subjected to clinical history and examination, laboratory investigations and abdominal ultrasound. Serum of all infants and children was tested for measurement of antiprothrombin antibody and anti-b2-glycoprotein I (ab2GPI) and anticardiolipin (ACL) auto-antibodies using a fully-automated enzyme linked immunosorbent assay (ELISA) system.

Results
The mean age of the infants with cholestatic liver diseases was significantly lower than those with metabolic liver diseases, hepatitis C virus (HCV) and vascular liver diseases (p < 0.05). The gender distribution was proportionate in all groups (p = 0.703). Autoantibodies showed significant variations among different etiologies of chronic liver diseases. he incidence of ab2GPI and ACL was significantly increased in both HCV (94.7% and 78.9%, respectively) and vascular liver diseases patients (90.9% and 72.7%, respectively) (p < 0.05). Antiprothrombin antibodies were found in 81.8% of vascular liver disease patients. Interestingly, all types of autoantibodies were deficient in cholestatic and metabolic liver diseases.

Conclusions
Testing for liver-related autoantibodies should be included in the workup of patients with chronic liver diseases. Further studies are needed to explain the cause-effect association of ACL, ab2GPI and antiprothrombin with chronic HCV and vascular liver diseases.

keywords:

antiprothrombin antibodies, anti-b2-glycoprotein antibodies, anticardiolipin antibodies, non-autoimmune liver diseases
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.